Facts & Stats

• Aminoadamantanes were first synthesized in the 1950s and include FDA-approved amantadine, rimantadine and memantine.
• Over 6 million people in the U.S. suffer from chronic neurodegenerative diseases such as dementia and Parkinson’s disease.
• Adamas is developing Advantaged Therapeutics for dementia and Parkinson’s disease that are designed to provide improved efficacy and tolerability and to simplify daily drug regimens.